A randomized trial to evaluate the efficacy & safety of Pemetrexed and Platinum Vs Gefitinib in Non-Small Cell Lung Cancer patients

Trial Profile

A randomized trial to evaluate the efficacy & safety of Pemetrexed and Platinum Vs Gefitinib in Non-Small Cell Lung Cancer patients

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs Gefitinib (Primary) ; Cisplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2017 Details of Qtwist (quality-adjusted time without symptom or toxicity) analysis method comparing the benefit of gefitinib versus pemetrexed platinum for this trial, presented at the 18th World Conference on Lung Cancer.
    • 06 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top